1499.8000 -32.30 (-2.11%)
NSE Nov 21, 2025 11:41 AM
Volume: 48,735
 

1499.80
-2.11%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. has gained 35.78% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended